Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 180(5): 1656-64, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10515829

ABSTRACT

The RTS,S/SBAS2 vaccine confers sterile protection against Plasmodium falciparum sporozoite challenge. The mechanisms underlying this are of great interest, yet little is known about the immune effector mechanisms induced by this vaccine. The immune responses induced by RTS,S/SBAS2 were characterized in 10 malaria-naive volunteers. Several epitopes in the circumsporozoite protein (CSP) were identified as targets of cultured interferon (IFN)-gamma-secreting CD4+ T cells. RTS,S-specific IFN-gamma-secreting effector T cells were induced in 8 subjects; this ex vivo response mapped to a single peptide in Th2R. CSP-specific CD8+ cytotoxic T lymphocytes were not detected. RTS, S-specific IFN-gamma production was universal, whereas interleukin-4 and -5 production was rare. RTS,S-specific lymphoproliferative responses and antibodies to CSP were strongly induced in all volunteers. Responses waned with time but were boostable. Thus, RTS, S/SBAS2 is a potent inducer of Th1-type cellular and humoral immunity. These results highlight possible immune mechanisms of protection and have important implications for vaccine design in general.


Subject(s)
Antibodies, Protozoan/blood , Malaria Vaccines/immunology , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Th1 Cells/immunology , Vaccines, Synthetic/immunology , Adult , Amino Acid Sequence , Animals , CD4-Positive T-Lymphocytes/immunology , Epitopes/chemistry , Hepatitis B Surface Antigens/immunology , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , Malaria Vaccines/administration & dosage , Malaria, Falciparum/prevention & control , Middle Aged , Molecular Sequence Data , Peptides/immunology , T-Lymphocytes, Regulatory/immunology , Vaccination , Vaccines, Synthetic/administration & dosage
2.
Clin Infect Dis ; 24(2): 135-9, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9114136

ABSTRACT

We determined the prevalence of herpes simplex virus (HSV) and cytomegalovirus (CMV) antibodies in a cohort of adolescents 12 to 22 years of age in anticipation of the development of vaccines to control HSV and CMV infections. For the overall study population, we found that 62% were seropositive for HSV type 1 (HSV-1), 12% were seropositive for HSV type 2 (HSV-2), and 65% were seropositive for CMV. Race was not related to HSV-1 seropositivity, but African-American adolescents were more likely than Caucasian adolescents to be seropositive for HSV-2 and CMV. Girls also were more likely than boys to be seropositive for HSV-2 and CMV. For boys, history of a sexually transmitted disease was identified as a risk factor for HSV-2 seropositivity; for girls, a greater number of sexual partners increased the risk of being seropositive for HSV-2. Our data demonstrating a high prevalence of infection during adolescence suggest that immunization for HSV-1, HSV-2, and CMV may need to occur in childhood.


Subject(s)
Antibodies, Viral/blood , Cytomegalovirus/immunology , Herpesvirus 1, Human/immunology , Herpesvirus 2, Human/immunology , Adolescent , Adult , Age Factors , Child , Cytomegalovirus Infections/etiology , Female , Herpes Genitalis/etiology , Humans , Male , Risk Factors , Sex Factors
3.
Cell Immunol ; 132(2): 339-49, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1824828

ABSTRACT

We investigated the effect of polymorphonuclear neutrophils (PMN) on anti-CD3 mAb (OKT3 and anti-Leu4)-mediated T cell activation. In the absence of monocytes, purified E-rosette-positive cells (further referred to as "T cells") require either solid-phase bound anti-CD3 or the combination of both a high concentration of soluble anti-CD3 and exogenous recombinant interleukin 2 (rIL-2) to proliferate. PMN cannot sustain T cell proliferation with soluble anti-CD3, but they markedly boost proliferation in the presence of soluble anti-CD3 and rIL-2. When PMN were added to T cell cultures stimulated with anti-CD3, this resulted in IL-2 receptor (IL-2R) expression and CD3 modulation. The mechanism of enhancement of anti-CD3-induced IL-2-responsiveness by PMN was further analyzed. A cellular T cell-PMN interaction was found to play a critical role and this was mediated through PMN Fc receptors (FcR). PMN bear two types of low-affinity FcR (FcRII and FcRIII). FcRII is known to bind mIgG1 (e.g., anti-Leu4) and FcRIII binds mIgG2a (e.g., OKT3). FcR involvement was demonstrated by two observations. Anti-FcRII mAb IV.3 inhibited the PMN signal for T cell activation with anti-Leu4. PMN bearing the second variant of FcRII which is unable to bind mIgG1 failed to promote anti-Leu4/IL-2-mediated T cell proliferation. Thus, PMN potentiate T cell responsiveness to IL-2 in the presence of anti-CD3 mAb and this potentiation by PMN requires interaction of anti-CD3 with PMN-FcR.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Differentiation, T-Lymphocyte/immunology , Lymphocyte Activation , Neutrophils/physiology , Receptors, Antigen, T-Cell/immunology , Receptors, Fc/physiology , T-Lymphocytes/immunology , Animals , Antigens, Differentiation, T-Lymphocyte/analysis , CD3 Complex , Humans , Interleukin-2/pharmacology , Mice , Receptors, Antigen, T-Cell/analysis , Receptors, Interleukin-2/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...